IL-233 is a novel hybrid cytokine of the two (IL-2+IL-33 [170]) Treatment of mice with IL-233 resulted in an expanded population of Tregs in lymphoid organs and renal compartments, and protection (decreased BUN, creatinine, and lower acute tubular necrosis) compared to vehicle treated cisplatin-induced AKI [170]. This evidence concerns the gene IL2 and acute kidney injury.